Cytochrome P450 Genotyping by Multiplexed Real-Time DNA Sequencing with Pyrosequencing™ Technology

Assay and Drug Development Technologies

Volumn 1, Issue 1, 2002, Pages 49-59

  Eriksson, Solveig ^a   Berg, Lars M ^a   Wadelius, Mia ^b   Alderborn, Anders ^a  

^a Pyrosequencing AB   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 2D6; DNA; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; COMPUTER SYSTEM; DNA SEQUENCE; GENETICS; HUMAN; METHODOLOGY; PHARMACOGENETICS; PHENOTYPE; REPRODUCIBILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; COMPUTER SYSTEMS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DNA; HUMANS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 0042843050     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/154065802761001301     Document Type: Article

References (37)

1. Huckle D: Molecular diagnostics: the catalyst that sparks the revolution? Pharm Vis 2001;winter edition:14–17.
2. Bertz R, Granneman GR: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210–258.
3. Ingelman-Sundberg M, Daly AK, Nebert DW: Home page of the human cytochrome P450 (CYP) allele nomenclature committee, http://www.imm.ki.se/CYPalleles/.
4. Ingelman-Sundberg M, Oscarsson M, McLellan RA: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;8:342–349.
5. Flockhart DA: Cytochrome P450 Drug Interaction Table, http://medicine.iupui.edu/flockhart/.
6. Marez D, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, Lafitte J-J, Meyer UA, Broly F: Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193–202.
7. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90:11825–11829.
8. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM: Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996; 392:30–34.
9. Sachse C, Brockmöller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284–295.
10. Griese E-U, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, Stüven T, Eichelbaum M: Assessment of the predictive power of genotypes for the in-vivo catalytic function of Cyp2D6 in a German population. Pharmacogenetics 1998;8:15–26.
11. Crespi CL, Miller VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997;7:203–210.
12. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717–719.
13. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwartz UI: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001;60:382–387.
14. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA: Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001;11:803–808.
15. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA: A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998;284:356–361.
16. x perspective. Expert Rev Mol Diag 2001;1:255–263.
17. x perspective. Expert Rev Mol Diagn 2001;1:371–376.
18. Ronaghi M, Uhlén M, Nyrén P: A sequencing method based on real-time pyrophosphate. Science 1998;281:363–365.
19. Alderborn A, Kristofferson A, Hammerling U: Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing. Genome Res 2000;10:1249–1258.
20. Nyrén, P: Enzymatic method for continuous monitoring of DNA polymerase activity. Anal Biochem 1987;167:235–238.
21. Berg LM, Sanders R, Alderborn A: Pyrosequencing technology and the need for versatile solutions in molecular clinical research. Expert Rev Mol Diagn 2002;2:361–369.
22. Gruber JD, Colligan PB, Wolford JK: Estimation of single nucleotide polymorphism allele frequency in DNA pools using Pyrosequencing. Hum Genet 2002;110:395–401.
23. Neve B, Froguel P, Corset L, Vaillant E, Vatin V, Boutin P: Rapid SNP allele frequency determination in genomic DNA pools by Pyrosequencing. Biotechniques 2002;32: 1138–1142.
24. Wasson J, Skolnick G, Love-Gregory L, Permutt MA. Assessing allele frequencies of single nucleotide polymorphisms in DNA pools by Pyrosequencing technology. Biotechniques 2002;32:1144–1150.
25. Pielberg G, Olsson C, Syvänen A-C, Andersson L: Unexpectedly high allelic diversity at the KIT locus causing dominant white colour in the domestic pig. Genetics 2002;160: 305–311.
26. Pourmand N, Elahi E, Davis RW, Ronaghi M. Multiplex Pyrosequencing. Nucleic Acids Res 2002;30:e31.
27. Wolf CR, Moss JE, Miles JS, Gough AC, Spurr NK: Detection of debrisoquine hydroxylation phenotypes. Lancet 1990;336:1452–1453.
28. Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, Sturman SG, Schapira AH, Williams AC, et al.: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375–1377.
29. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR: Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990; 347:773–776.
30. Yasar U, Elisson E, Dahl M-L, Johansson I, Ingelman-Sundberg M, Sjökvist F: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem and Biophys Res Commun 1999:254:628–631.
31. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M: Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57:656–661.
32. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594–598.
33. Inbar E, Yakir B, Darvasi A: An efficient haplotyping method with DNA pools. Nucleic Acids Res 2002;30:e76.
34. Pettersson M, Bylund M, Alderborn A: Molecular haplotype determination using allele-specific PCR and Pyrosequencing technology. Submitted.
35. Nasu K, Kubota T, Ishizaki T: Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997;7:405–409.
36. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfeld GM, Miners JO, Birkett DJ, Goldstein JA: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341–349.
37. Goldstein JA, Blaisdell J: Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 1996;272:210–218.